NCT03614910View on ClinicalTrials.gov

Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2021

Conditions
Pancreatic Cancer
Interventions
DEVICE

Nanoknife Irreversible Electroporation

Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor

Trial Locations (1)

07666

Holy Name Medical Center, Teaneck

All Listed Sponsors
lead

Holy Name Medical Center, Inc.

OTHER

NCT03614910 - Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System | Biotech Hunter | Biotech Hunter